Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCC4 | O15439 | 1/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 3/20 | 0.33 |
| ▸ | TP53 | P04637 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | SHMT2 | P34897 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8106789 | 0.88 | ABCC4 (0.43) | ABCC4PTGS1MAOAMAOB | |
| SCHEMBL31151882 | 0.80 | MAOA (0.59) | ABCC4PTGS1MAOAMAOBLMNA | |
| SCHEMBL1648508 | 0.80 | MAOA (0.59) | ABCC4PTGS1MAOAMAOBLMNA | |
| SCHEMBL16348648 | 0.77 | MAOA (0.46) | MAOAMAOB | |
| SCHEMBL194519 | 0.76 | MAOA (0.65) | MAOAMAOBLMNA | |
| SCHEMBL8113246 | 0.72 | ABCC4 (0.40) | ABCC4PTGS1MAOAMAOBLMNA | |
| SCHEMBL2760383 | 0.72 | ABCC4 (0.59) | ABCC4PTGS1MAOAMAOBLMNA | |
| SCHEMBL8116106 | 0.71 | MAOA (0.52) | ABCC4PTGS1MAOAMAOB | |
| SCHEMBL8114347 | 0.71 | ABCC4 (0.39) | ABCC4PTGS1MAOAMAOB | |
| SCHEMBL15062681 | 0.71 | MAOA (0.45) | MAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0991793-B1 | METHOD FOR PREPARING 2-ARYL OR 2-HETEROCYCLYL CHIRAL PROPIONIC ACIDS AND THEIR ESTERS | CT NAT DE BR LA RECH SCIENT (FR) | 2001-12-05 | — | — | EP | claimed |
| US-6294069-B1 | MIXTURE OF PROPIONIC ACID DERIVATIVE IS ELECTROCHEMICALLY REDUCED IN THE PRESENCE OF NICKEL COMPLEX CATALYST AND SUPPORTING ELECTROLYTE IN ELECTROLYSIS CELL PROVIDED WITH ELECTRODES, PRODUCT IS HYDROLYZED OR TRANSESTERIFIED | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2001-09-25 | — | — | US | claimed |
| EP-0751944-B1 | THIAZOLIDINES AND OXAZOLIDINES SUBSTITUTED BY A PYRIDINE RING AND THEIR USE AS HYPOGLYCEMIC AGENTS | NISSAN CHEMICAL IND LTD (JP) | 2000-12-20 | — | — | EP | claimed |
| EP-0751944-A1 | THIAZOLIDINES AND OXAZOLIDINES SUBSTITUTED BY A PYRIDINE RING AND THEIR USE AS HYPOGLYCEMIC AGENTS | NISSAN CHEMICAL INDUSTRIES, LIMITED (JP) | 1997-01-08 | — | — | EP | claimed |
| WO-1995026347-A1 | THIAZOLIDINES AND OXAZOLIDINES SUBSTITUTED BY A PYRIDINE RING AND THEIR USE AS HYPOGLYCEMIC AGENTS | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 1995-10-05 | — | — | WO | claimed |
| US-20140057959-A1 | NOVEL COMPOUNDS DERIVED FROM TAURINE, PROCESS OF THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE | UNIVERSIDADE ESTADUAL PAULISTA JULIO DE MESQUITA FILHO - UNESP (BR) | 2014-02-27 | — | — | US | disclosed |
| US-6294069-B1 | MIXTURE OF PROPIONIC ACID DERIVATIVE IS ELECTROCHEMICALLY REDUCED IN THE PRESENCE OF NICKEL COMPLEX CATALYST AND SUPPORTING ELECTROLYTE IN ELECTROLYSIS CELL PROVIDED WITH ELECTRODES, PRODUCT IS HYDROLYZED OR TRANSESTERIFIED | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2001-09-25 | — | — | US | disclosed |
| EP-0751944-B1 | THIAZOLIDINES AND OXAZOLIDINES SUBSTITUTED BY A PYRIDINE RING AND THEIR USE AS HYPOGLYCEMIC AGENTS | NISSAN CHEMICAL IND LTD (JP) | 2000-12-20 | — | — | EP | disclosed |
| EP-0751944-A1 | THIAZOLIDINES AND OXAZOLIDINES SUBSTITUTED BY A PYRIDINE RING AND THEIR USE AS HYPOGLYCEMIC AGENTS | NISSAN CHEMICAL INDUSTRIES, LIMITED (JP) | 1997-01-08 | — | — | EP | disclosed |
| WO-1996026207-A1 | THIAZOLIDINE AND OXAZOLIDINE INDOLES WITH HYPOCLYCEMIC ACTIVITY | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 1996-08-29 | — | — | WO | disclosed |
| WO-1996011196-A1 | PYRAZOLYLMETHYL-THIAZOLIDINES USEFUL AS HYPOGLYCEMIC AGENTS | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 1996-04-18 | — | — | WO | disclosed |
| WO-1995026347-A1 | THIAZOLIDINES AND OXAZOLIDINES SUBSTITUTED BY A PYRIDINE RING AND THEIR USE AS HYPOGLYCEMIC AGENTS | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 1995-10-05 | — | — | WO | disclosed |
| EP-0286944-B1 | NEW PROCESS FOR THE PREPARATION OF 2-ARYL-PROPIONIC ACIDS | ENICHEM SYNTHESIS S.p.A. (IT) | 1992-07-08 | — | — | EP | disclosed |
| US-5089661-A | Catalytically hydrogenating complex salt of corresponding hydroxy acid; bi- or tri-valent metal cations | ENICHEM SYNTHESIS S.P.A. (IT) | 1992-02-18 | — | — | US | disclosed |
| EP-0286944-A2 | New process for the preparation of 2-aryl-propionic acids | ENICHEM SYNTHESIS S.p.A. (IT) | 1988-10-19 | — | — | EP | disclosed |
| US-4711879-A | IMMUNO-MODULATING ACTIVITY | CIBA-GEIGY CORPORATION (US) | 1987-12-08 | — | — | US | disclosed |
| US-4640911-A | IMMUNOSTIMULANTS, VIRICIDES SUCH AS HERPES SIMPLEX | CIBA-GEIGY CORPORATION (US) | 1987-02-03 | — | — | US | disclosed |
| EP-0163286-A2 | Acylated sugars, method for their preparation and their use | CIBA-GEIGY AG (CH) | 1985-12-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140057959-A1 | NOVEL COMPOUNDS DERIVED FROM TAURINE, PROCESS OF THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE | TPMT, UTS2R, NSUN3 | ABCC4 2890/4885PTGS1 44/4885MAOA 791/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.